JP2019504837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504837A5 JP2019504837A5 JP2018537845A JP2018537845A JP2019504837A5 JP 2019504837 A5 JP2019504837 A5 JP 2019504837A5 JP 2018537845 A JP2018537845 A JP 2018537845A JP 2018537845 A JP2018537845 A JP 2018537845A JP 2019504837 A5 JP2019504837 A5 JP 2019504837A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- phosphorothiolate
- gspp
- independently selected
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004999 messenger RNA Proteins 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 101150087322 DCPS gene Proteins 0.000 claims 2
- -1 N 3 Chemical group 0.000 claims 2
- 101100386724 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nhm1 gene Proteins 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415967A PL415967A1 (pl) | 2016-01-29 | 2016-01-29 | 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie |
| PLPL415967 | 2016-01-29 | ||
| PCT/IB2017/050447 WO2017130151A1 (en) | 2016-01-29 | 2017-01-27 | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504837A JP2019504837A (ja) | 2019-02-21 |
| JP2019504837A5 true JP2019504837A5 (enExample) | 2020-01-23 |
| JP7144050B2 JP7144050B2 (ja) | 2022-09-29 |
Family
ID=58387852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537845A Active JP7144050B2 (ja) | 2016-01-29 | 2017-01-27 | ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11066436B2 (enExample) |
| EP (1) | EP3408276B1 (enExample) |
| JP (1) | JP7144050B2 (enExample) |
| KR (1) | KR102742219B1 (enExample) |
| CN (1) | CN109071589A (enExample) |
| AU (1) | AU2017211693B2 (enExample) |
| CA (1) | CA3011663C (enExample) |
| EA (1) | EA038834B1 (enExample) |
| ES (1) | ES2879802T3 (enExample) |
| PL (2) | PL415967A1 (enExample) |
| WO (1) | WO2017130151A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020231697A1 (en) * | 2019-05-10 | 2020-11-19 | New England Biolabs, Inc. | Chemical capping for template switching |
| CN110907358B (zh) * | 2019-12-09 | 2022-08-30 | 福建师范大学 | 一种光微流微泡腔铅离子传感器的实现装置及方法 |
| PL432884A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN113355380A (zh) * | 2020-08-20 | 2021-09-07 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| EP4208549A4 (en) | 2020-09-04 | 2025-04-16 | Verve Therapeutics, Inc. | Compositions and methods for capping RNAs |
| CN119137271A (zh) * | 2022-03-01 | 2024-12-13 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| CN116143855B (zh) * | 2022-11-08 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用 |
| EP4464713A1 (en) | 2023-05-18 | 2024-11-20 | Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii | Circular rna analogs, preparation and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1907584A2 (en) | 2005-06-28 | 2008-04-09 | Agencourt Personal Genomics Corporation | Methods of producing and sequencing modified polynucleotides |
| SI2167523T1 (sl) * | 2007-06-19 | 2014-09-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Sinteza in uporaba anti-reverznih fosforotioatnih analogov kape obveščevalne RNA |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US10266559B2 (en) * | 2013-03-14 | 2019-04-23 | Translate Bio, Inc. | Ribonucleic acids with 4′-thio-modified nucleotides and related methods |
| WO2015021432A1 (en) | 2013-08-08 | 2015-02-12 | The Scripps Research Institute | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
-
2016
- 2016-01-29 PL PL415967A patent/PL415967A1/pl unknown
-
2017
- 2017-01-27 JP JP2018537845A patent/JP7144050B2/ja active Active
- 2017-01-27 EA EA201891429A patent/EA038834B1/ru unknown
- 2017-01-27 AU AU2017211693A patent/AU2017211693B2/en active Active
- 2017-01-27 WO PCT/IB2017/050447 patent/WO2017130151A1/en not_active Ceased
- 2017-01-27 PL PL17712541T patent/PL3408276T3/pl unknown
- 2017-01-27 EP EP17712541.6A patent/EP3408276B1/en active Active
- 2017-01-27 US US16/073,499 patent/US11066436B2/en active Active
- 2017-01-27 CA CA3011663A patent/CA3011663C/en active Active
- 2017-01-27 KR KR1020187021714A patent/KR102742219B1/ko active Active
- 2017-01-27 ES ES17712541T patent/ES2879802T3/es active Active
- 2017-01-27 CN CN201780013350.3A patent/CN109071589A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504837A5 (enExample) | ||
| AU2020204111B2 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| US20220396556A1 (en) | Lipid and Lipid Nanoparticle Formulation for Drug Delivery | |
| JP2013510123A5 (enExample) | ||
| JP2016513737A5 (enExample) | ||
| CN114085198A (zh) | 用于递送核酸的脂质和脂质纳米颗粒制剂 | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| CA2969664A1 (en) | Cationic lipid | |
| CN111447920A (zh) | 具有高活性物质负载量的口服薄膜 | |
| US20250059131A1 (en) | Fluorinated cationic lipids for use in lipid nanoparticles | |
| TW201008582A (en) | Docetaxel polymer derivative, method for producing same and use of same | |
| CA3238292A1 (en) | Novel ionizable lipids and lipid nanoparticles and methods of using the same | |
| RU2009145541A (ru) | Терапевтические соединения | |
| EP4647421A1 (en) | Compound for delivering drug, and liposome and drug carrier | |
| US20250275918A1 (en) | Lipid compositions and methods for nucleic acid delivery | |
| WO2022032058A1 (en) | Multicomponent delivery systems for polyanionic cargo compound delivery | |
| JP2017503753A5 (enExample) | ||
| WO2023114188A1 (en) | Ionizable lipids and compositions and uses thereof | |
| JP2022501390A (ja) | 化合物及びその用途 | |
| CN120265611A (zh) | 脂质化合物及其用途 | |
| RU2009145537A (ru) | Терапевтические соединения | |
| JP6837962B2 (ja) | 活性薬剤の送達のための両親媒性ブロックコポリマー | |
| JP2011500841A5 (enExample) | ||
| US20240307526A1 (en) | Compositions comprising hydroxyethyl-capped cationic peptoids | |
| EP4619378A2 (en) | Ionizable lipids and lipid nanoparticle compositions for the delivery of nucleic acids |